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ABSTRACT
Hepatitis B virus (HBV) reactivation is a clinical problem associated with high morbidity and mortality rates. 
Currently, this incidence seems to be increasing around the world. The reactivation commonly developes in 
immunosuppressed individuals, although it may also occur spontaneously. Individuals who develop malignancy 
with chronic hepatitis B virus infection are at high-risk for hepatitis B virus reactivation, since they are closely 
related to immunosuppression, especially when undergoing chemotherapy. The loss of immune control in these 
patients may results in the reactivation of HBV replication within hepatocytes. This review article will focus on 
HBV reactivation related to immunosuppressed patients, immunosuppressive drug classes and corresponding 
risk estimates of hepatitis B virus reactivation, screening test recommended before getting this drugs, choice of 
antiviral drugs for prophylaxis, and duration of prophylaxis treatment based on European Association for the 
Study of the Liver (EASL), American Association for the Study of Liver Diseases (AASLD), and  Asian Pacific 
for the Study of the Liver (APASL) guidelines.
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ABSTRAK
Reaktivasi hepatitis B adalah merupakan masalah klinis dengan morbiditas dan mortalitas yang tinggi. 
Akhi-akhir ini angka kejadian reaktivasi virus hepatitis B (VHB) tampak meningkat di seluruh dunia. Reaktivasi 
VHB sangat sering terjadi pada individu dengan kondisi imun tersupresi, walaupun juga bisa terjadi secara 
spontan. Individu yang mempunyai penyakit keganasan dan hepatitis kronis B mempunyai risiko tinggi untuk 
terjadi reaktivasi VHB, khususnya jika menjalani prosedur khemoterapi. Mekanisme yang mendasari terjadinya 
reaktivasi adalah hilangnya kontrol imun atas replikasi VHB di hepatosit. Review artikel ini akan membahas 
tentang reaktivasi VHB terkait imunosupresan, jenis kelas obat-obat imunosupresan apa saja yang mempunyai 
risiko dan prediksi besarnya risiko terjadinya reaktivasi VHB, pemeriksaan yang diperlukan untuk skrining 
pada pasien-pasien sebelum menjalani kemoterapi, pemilihan jenis antiviral dan berapa lama pemberian terapi 
profilaksis untuk mencegah terjadinya reaktivasi VHB dari berbagai guideline yang dikeluarkan oleh European 
Association for the Study of the Liver (EASL), American Association for the Study of Liver Diseases (AASLD), 
dan Asian Pacific for the Study of the Liver (APASL).
Kata kunci: reaktivasi hepatitis B, imunosupresif, kemoterapi, profilaksis, terapi
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INTRODUCTION
Hepatitis B virus is a DNA virus which could lead 
to potentially life-threatening liver infection.1 Hepatitis 
B virus infection is a major public health problem 
worldwide that needs special concern. Roughly 30% 
of the world’s population show serological evidence 
of current or past infection.2 Approximately 350-
400 millions people live with chronic infection. An 
estimated 600.000 people die each year due to the acute 
or chronic consequences of hepatitis B virus infection.1
Chronic hepatitis B virus infection could 
lead to progressive liver damage, but mostly 
(60-85%) are asymptomatic. That is why it becomes 
undetectable, until signs and symptoms of chronic 
liver disease/cirrhosis appear.2 However, hepatitis 
B virus reactivation in this population may occur, 
either spontaneously or upon immunosuppression. 
Impairment of the host immune system due to treatment 
with chemotherapeutic or immunosuppressive agents 
raises the risk of HBV reactivation. The consequences 
of hepatitis B virus reactivation range from self-limited 
conditions to fulminant hepatic failure and death.4,5
HEPATITIS B VIRUS REACTIVATION
Hepatitis B virus reactivation is a sudden increase 
of hepatitis B virus DNA (more than 10-fold) in 
serum, or reappearance of hepatitis B virus DNA in the 
serum, commonly accompanied by increase of alanine 
transaminase (ALT) level in patient with inactive or 
resolved hepatitis B. The increase of ALT level is 
characterized by threefold rise above the upper limit 
of normal value or an absolute increase more than 
100 U/L. Also, previously HBeAg-negative patients 
become HBeAg-positive. To diagnose hepatitis 
attributed to hepatitis B virus reactivation, clinicians 
must exclude other possible causes, such as evidence 
of hepatic infiltration by underlying malignancy, 
administration of hepatotoxic drugs, recent history of 
transfusion, and presence of other systemic infections. 
For patients with HBsAg-negative and HBcAg-
positive, hepatitis B virus reactivation is characterized 
by reappearance of HBsAg with the increase of ALT 
level in two measurements over a period of 5 days, 
and increase of hepatitis B virus DNA more than 105 
copies/mL.4,5,6
Hepatitis B reactivation has been described 
as a three-phase event (Figure 1). Initially, an 
increased HBV DNA levels in an HBsAg positive 
person is found, or reappearance of either HBsAg 
(seroconversion) or HBV DNA occurs; this period is 
usually asymptomatic. When the following phase takes 
places, HBV DNA levels show a sustained increase in 
viral load, accompanied by concomitant elevations in 
aminotransferase levels, which may also be associated 
to the development of severe hepatocellular damage; 
to note, even acute liver failure and ultimately death 
may occur. The aforementioned events result from a 
reconstitution syndrome of the host immune response. 
Finally, liver damage resolves due to recovery of the 
immune system strength (spontaneously or as a result 
of immunosuppressive therapy suspension) or due to 
administration of antiviral drugs. [2]
 
 
 3 
with HBsAg-negative and HBcAg-positive, hepatitis B virus reactivation is characterized by 
reappearance of HBsAg with the increase of ALT level in two measurements over a period of 5 days, 
and increase of hepatitis B virus DNA more than 105 copies/mL.4,5,6 
Hepatitis B reactivation has been described as a three-phase event (Figure 1).  Initially, an 
increased HBV DNA levels in an HBsAg positive person is found, or reappearance of either HBsAg 
(seroconversion) or HBV DNA occurs; this period is usually asymptomatic. When the following phase 
takes places, HBV DNA levels show a sustained increase in viral load, accompanied by concomitant 
elevations in aminotransferase levels, which may also be associated to the development of severe 
hepatocellular damage; to note, even acute liver failure and ultimately death may occur. The 
aforementioned events result from a reconstitution syndrome of the host immune response. Finally, 
liver damage resolves due to recovery of the immune system strength (spontaneously or as a result of 
immunosuppressive therapy suspension) or due to administration of antiviral drugs. [2] 
 
 
Figure 1. Hepatitis B reactivation phases. In the initial phase, there is an increase in HBV DNA levels, usually 
with an asymptomatic evolution. In the second phase,both ALT and HBV DNA are elevated; symptoms are 
frequently present, and they may be severe. The third phase is determined by resolution, although HBsAg (if 
reappeared), or elevated HBV DNA, may persist. IS: Immunosuppression; HBV: Hepatitis B virus; ALT: Alanine 
aminotransferase; HBsAg: Hepatitis B surface Antigen  [2] 
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The causes of hepatitis B virus reactivation 
are varied, although this could be spontaneous, in 
most patients who develop viral reactivation, due 
to imbalance between host immunity and hepatitis 
B virus activity. This imbalance may be induced by 
immunosuppressive agents, cytotoxic chemotherapy, 
HIV infection, or sudden withdrawal of antiviral 
therapy.4 Clinically, hepatitis B virus reactivation varies 
from asymptomatic elevation of serum ALT to acute 
liver failure and death.1
CHEMOTHERAPY-RELATED REACTIVATION OF 
HEPATITIS B VIRUS INFECTION
Malignant cancer is a worldwide disease and in 
developing countries one in three people will develop 
cancer during their lifetimes.7 Over the last decades, 
chemotherapy has demonstrated a significant role in 
malignancy treatment and may prolong life expectancy. 
It is estimated that 1 in 4 patients with malignancy and 
chronic hepatitis B infection in Japan develop infection 
reactivation due to receiving chemotherapy. Hepatitis 
igure 1. Hepatitis B reactiva io  pha s. In the initial phase, there 
is an increase in HBV DNA levels, usually with an asymptomatic 
evolution. In the second phase,both ALT and HBV DNA are elevated; 
symptoms are frequently prese t, and they may be severe. The third 
phase is determined by resolution, although HBsAg (if reappeared), 
or elevated HBV DNA, may persist. IS: Immun suppression; HBV: 
Hepatitis B virus; ALT: Alanine aminotransferase; HBsAg: Hepatitis 
B surface Antigen [2]
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B virus reactivation during anticancer treatment may 
results in life-threatening events and poor outcome due 
to early discontinuation of chemotherapy.6,8
The first prospective study on hepatitis B virus 
reactivation was published in 1991, and included 
Chinese patients with malignant lymphoma who 
received chemotherapy. Hoofnagle et al described 2 
cases of hepatitis B virus reactivation in asymptomatic 
hepatitis B virus carriers within 3 months of starting 
chemotherapy. Several other studies have shown 
that the median interval between the initiation of 
chemotherapy and the onset of reactivation was 4 
months (1–9 months). The rate of hepatitis B virus 
reactivation in patients with chronic hepatitis B virus 
infection who have positive serum HBsAg ranges from 
24–88%, and in patients who are anti-HBc-positive 
ranges from 3–22%. The mortality rate in HBV 
reactivation ranges from 23–71%.1
Usually, HBV viral loads increase when patients 
receive immunosuppressants or chemotherapy. After 
withdrawal of such treatments, the host immune 
response rebounds, and hepatitis flare develops.4 This 
viral replication occurs after the start of chemotherapy 
due to suppressed cellular immune response, the 
spread of hepatitis B virus to hepatocytes and 
rising serum hepatitis B virus DNA levels. These 
modifications may occur up to three weeks earlier than 
laboratory alterations and may be accompanied by 
serological reappearance of HBeAg and HBsAg. After 
chemotherapy withdrawal, the immunological function 
of host is restored leading to cytotoxic-T-cells mediated 
destruction of hepatitis B virus infected hepatocytes. 
This results in increasing ALT levels (hepatic flare) and 
may cause several clinical manifestations that could 
range from mild to severe, such as fulminant hepatic 
failure or even death.5,8 During this phase, HBV DNA 
levels may decrease.8
The risk factors for hepatitis B virus reactivation 
have not been clearly identified. The key to prevent 
HBV reactivation is the timely identification of HBV-
infected patients prior to immunosuppressive therapy. 
Risk factors associated with HBV reactivation have 
been less described. Risk factors for HBV reactivation 
in patients with current/past hepatitis B infection are 
included in Table 1.2
Most of the risk factors identified to date are 
based on case studies of small sample size. Hepatitis 
B virus reactivation usually occurs after the second 
or third course of chemotherapy [1]. Several clinical 
predictors of hepatitis B virus reactivation have been 
identified, including a certain serum HBV DNA level 
prior to immunosuppression, the type of underlying 
malignancy, the regimen of chemotherapy, and the 
intensity of immunosuppression. Generally, risk factors 
for anticancer chemotherapy-related hepatitis B virus 
reactivation could be divided into several categories as 
follows, host factors, type of malignancy or treatment-
related factors, as well as viral factors.3 Studies 
conducted by Yeo et al and Matsue et al showed risk 
factors for hepatitis B virus reactivation in patients with 
negative HBsAg/positive HbcAb, especially related to 
male gender and rituximab use and negative anti-HBs.5
Table 1. Risk factors for anticancer chemotherapy-related 
hepatitis B virus reactivations3,5
Categories Risk factors
Host factors Male gender
Young age
Elevated baseline ALT
Tumour- or treatment-
related factors
Lymphoma
Haematological malignancies
Breast cancer
Glucocorticoid use
Anthracycline use
Rituximab-based regimen
Hematopoietic stem cell transplantation
TACE treatment for HCC
Viral factors High pre-chemotherapy viral load
Positive HBeAg
Presence of precore mutant
Negative or low titre of HBsAb (in case of 
occult/past infection)
CHEMOTHERAPEUTIC AGENTS ASSOCIATED 
WITH HEPATITIS B VIRUS REACTIVATION
Various types of chemotherapeutic agents may 
cause immunosuppressive state in patients that could 
induce hepatitis B virus reactivation in patients with 
chronic hepatitis B infection. Table 2 summarizes 
various types of chemotherapeutic agents that have 
been reported to cause hepatitis B virus reactivation.1
Those chemotherapeutic agents listed in Table 
2 have different magnitude of risk for hepatitis B 
virus reactivation in patients with positive HBsAg 
and negative HBsAg/positive anti-HBc. Several new 
chemotherapeutic agents (biological agents) such as 
B-cell depletion agents are potent immunosuppressants, 
that yield higher risk for hepatitis B virus reactivation. 
For instance, rituximab, is an agent predominantly 
used to treat haematological malignancy in addition 
to autoimmune and neurological disease.9,10 Rituximab 
is an agent that works against CD20 on B-cell. CD20 
positive B-cells depletion might reduce the number of 
CD4 memory cells, CD8 cells, and antibody-mediated 
immunity. It results in acceleration of hepatitis B 
virus replication during receiving rituximab-based 
chemotherapy. Rituximab-based chemotherapy has 
been reported to cause hepatitis B reactivation even 
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when administered alone or even in combination. The 
rate of hepatitis B virus reactivation during rituximab 
treatment when combined with chemotherapy has been 
reported to be 20-55% overall and 3% in patients with 
negative HbsAg.10,11
due to various chemotherapeutic/ immunosuppressive 
agents are shown in Table 2 and Figure 3.
Patients undergoing stem cell/bone marrow 
transplantation are at the highest HBVr-risk followed 
by those receiving solid organ transplantation. Bone 
marrow/stem cell transplanted patients typically 
need intense chemotherapy to induce remission of 
the underlying malignancy, followed by additional 
chemotherapy and radiation therapy to ablate bone 
marrow. This setting causes the rate of hepatitis B 
virus reactivation reaches 50% in both HBsAg-positive 
and HBsAg-negative with anti-HBc-positive patients. 
Anti-HBs titres below 10 mUI/mL are a predictor of 
HBsAg seroreversion in the group of patients with 
HBsAg-negative/anti-HBc-positive.2
Table 2. Chemotherapeutic agents associated with hepatitis B 
virus reactivation1
Class Name of drugs
Alkylating agents Chlorambucil, Cyclophosphamide, 
Ifosfamide, Mercaptopurine
Anthracyclines Doxorubicin, Daunorubicin, Idarubicin, 
Epirubicin
Antimetabolite 5-Fluorouracil, Methotrexate, Cytara-
bine, Gemcitabine
Antitumor antibiotic Actinomycin-D, Bleomycin, Mitomycin-C
Corticosteroids Prednisone, Dexamethasone, Methyl-
prednisolone
Platinum Cisplatin, Carboplatin
Taxane Paclitaxel, Docetaxel
Vinka Alkaloid Vincristine, Vinblastine
Other cytotoxic agents Etoposide, Procarbazine, Dacarbazine, 
Lomustine
Biologicals Rituximab, Alemtuzumab
Tyrosine kinase inhibitor Imatinib
Immune modulator Interferon, Thalidomide
Table 3. Immunosuppressive drug classes and corresponding risk estimates of hepatitis B virus reactivation9
Drug class Drug Risk estimate of HBVr for HBsAg +
Risk estimate of 
HBVr for HBsAg-
/anti-HBc +
B-cell depleting agents Rituximab (anti-CD20)
Ofatumumab (anti-CD20)
High (30-60%) High (>10%)
Anthracycline derivatives Doxorubicin
Epirubicin
High (15-30%) High (>10%)
TNF-α inhibitors Infliximab
Etanercept
Adalimumab
Moderate (1-10%) Moderate (1%)
Cytokine inhibitors and 
integrin inhibitors
Abatacept (anti-CD80,-86)
Ustekinumab (anti IL12,-23)
Natalizumab (bind α4-integrin)
Vedolizumab (bind integrin α4β7/LPAM-1)
Moderate (1-10%) Moderate (1%)
Tyrosine kinase inhibitors Imatinib
Nilotinib
Moderate (1-10%) Moderate (1%)
Corticosteroids High dose, e.g. prednisone ≥20mg for ≥4wk
Moderate dose, e.g. prednisone <20mg for ≥4wk
Low dose, e.g. prednisone <1wk
Intraarticular corticosteroids
High (>10%)
Moderate (1-10%)
Low (<1%)
Low (<1%)
Not available
Moderate (1-10%)
Low(<<1%)
Low (<<1%)
Traditional immunosup-
pression
Azathioprine
6-mercaptopurine
Methotrexate
Low (<1%) Low (<<1%)
Corticosteroids are the most commonly used 
immunosuppressants associated with hepatitis B virus 
reactivation through their effect on T-cell function, 
that also may enhance hepatitis B virus replication 
through their interaction with the hepatitis B virus 
glucocorticoid element (a transcriptional regulatory 
element). A study has demonstrated that a 4-weeks 
course of prednisone has been associated with hepatitis 
B virus reactivation in the post-withdrawal phase of 
prednisone and worsened liver histology. The rate 
of hepatitis B virus reactivation events in the setting 
of chronic airways disease due to chronic oral vs. 
inhaled steroid use is 11.1% and 3.2%, respectively.9 
The magnitude of risk of hepatitis B virus reactivation 
Figure 2. Immunosuppressing agents and related risk of hepa-
titis B reactivation2
*)Hepatitis B reactivation during administration of immunosuppressant agents 
with low doses of azathioprine or methotrexate as monotherapy is uncommon. In 
a recently published review, no report was found in which azathioprine user alone 
was documented to causa hepatitis B reactivation. Similarly, although report 
associated with methotrexate-induced hepatitis B reactivation are available, 
most of them involved the concomitant use of other imunomodulator (2)
*)Tumour necrosis factor a (TNF-α) is a pro-inflammatory and immunoregulatory 
cytokine involved in the patoghenesis of seberat inflammatory disorder. The 
inhibition of TNF-α signalling can lead to increased HBV replication and 
reactivation. ;
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PROPHYLAXIS AND MANAGEMENT OF HEPATITIS 
B VIRUS REACTIVATION
The rate of conversion to fulminant hepatitis as a 
result of hepatitis B virus reactivation and the mortality 
rate are estimated higher among patients with hepatitis 
B virus reactivation than among patients with acute 
hepatitis. It suggests that the prognosis of patients 
with hepatitis B virus reactivation who also develop 
liver damage is extremely poor, thus it is important 
to suppress reactivation before liver dysfunction is 
developed.6 Various ways to prevent hepatitis B virus 
reactivation in patients receiving immunosuppressive 
agents such as chemotherapy are required and have 
already been performed. These include some aspects, 
such as optimal screening in certain population 
requiring prophylactic therapy, selection of the most 
appropriate agent, duration of prophylaxis, type and 
duration of monitoring in high-risk population of 
patients who do not receive prophylaxis.1,12
Management guidelines originating from America, 
Europe, and the Asia-Pacific region recommend 
all cancer patients should be checked hepatitis B 
virus markers. These markers include HBsAg and 
anti-HBc, and should be checked prior to initiation 
of chemotherapy. Prophylactic antiviral therapy is 
recommended for individuals who are positive for 
HBsAg before the start of chemotherapy. The duration 
of antiviral prophylaxis must be extended for at least 
6 months after completing chemotherapy to avoid 
delayed HBV reactivation. It would be better to have 
a longer duration of antiviral therapy until treatment 
end points are reached, i.e. HBeAg seroconversion for 
HBeAg-positive, undetectable level of hepatitis B virus 
DNA and HBsAg loss for HBeAg-negative patients. 
It is highly recommended for patients with high viral 
loads at baseline (>2,000 IU/mL). For cases with low 
viral load at baseline and treatment duration is less 
than 12 months, antiviral drugs such as lamivudine or 
telbivudine could be used. Otherwise, antiviral drugs 
such as entecavir or tenofovir are preferred.4,8,12,13
In HbsAg-positive patients, duration could be 
determined by clinical indication as in immunocompetent 
patients. A 12-months treatment was only endorsed by 
EASL. Drug selection depends on treatment duration and 
clinical setting. In isolated anti-HBc-positive patients 
when treated with biologic agents, close follow-up and 
treatment if necessary, is suggested by AASLD/APASL; 
however EASL proposes that isolated anti-HBc-positive 
patients, if HBV-DNA-positive, anti-HBs-negative or 
undergoing rituximab/stem cell transplantation, should 
be treated with the same strategy as HbsAg positive 
patients; When monitored, treatment should start when 
HBV DNA becomes positive , before ALT rises (EASL); 
Treatment in all HBV-related HCC patients undergoing 
TACE is suggested by APASL guideline. Generally, 
individuals with HBsAg-negative/anti-HBc-positive 
except transplantation, have no recommendation yet 
to receive prophylactic antiviral therapy, but should be 
monitored continuously during chemotherapy to detect 
reactivation and administer prompt management.2
Table 4. Comparison of prophylaxis strategies against hepatitis B reactivation with recent major guidelines3
AASLD (2009) EASL (2012) APASL (2012)
Screening tests HBsAg, anti-HBc HBsAg, anti-HBc HBsAg, anti-HBc in rituximab or 
anti-TNFα-treated patients
Duration of therapy 6 mo after the completion of chemotherapy/
immunosuppression, if baseline HBV DNA 
<2000 IU/mL; continue treatment until treatment 
endpoints in immune competent patients if HBV 
DNA >2000 IU/mL
12 mo after cessation of 
chemotherapy
At least 24 wk after the end of 
chemotherapy
Antiviral agent Lamivudine/Telbivudine if duration of treatment 
≤12 mo and baseline HBV DNA is undetectable; 
tenofovir/entecavir if longer treatment duration 
is needed
Lamivudine if low HBV 
DNA (<2000 IU/mL) and 
a finite, short duration of 
immunosuppression is 
planned; entecavir/tenofovir 
if high HBV DNA and/or 
lengthy, repeated cycles 
of immunosuppression are 
planned
Lamivudine; entecavir/tenofovir 
can be used
Occult/past infection Monitor HBV DNA; treat if HBV DNA becomes 
detectable
Test for HBV DNA; if HBV 
DNA +, treat similarly 
for HBsAg + patients; 
if HBV DNA-negative, 
follow every 1-3 mo with 
ALT and HBV DNA and 
treat upon reactivation 
before ALT elevation; 
preemptive therapy can be 
given if monitoring is not 
guaranteed or in cases of 
stem cell transplantation 
Monitor HBV DNA; treat when 
needed
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There is no established recommendation for routine 
antiviral prevention for patients who are negative for 
HBsAg but positive for anti-HBc. Hepatitis B virus 
DNA should be checked in this group of patients, 
and continuous hepatitis B DNA monitoring must be 
performed to detect hepatitis B reactivation. Antiviral 
treatment should be started as soon as hepatitis B virus 
DNA has increased tenfold compared with baseline, and 
>2000 IU/mL during the course of chemotherapy.4,8,12,13 
Patients who will undergo bone marrow transplantation 
from non-immune donor are recommended to receive 
prophylactic therapy, while the recipient of liver graft 
with positive anti-HBc should receive HBIg in addition 
to prophylactic therapy.14 
CONCLUSION
HBV reactivation is a clinical problem associated 
with high morbidity and mortality rates. HBV 
Screening before starting immunosuppressive therapy 
is a key factor to prevent HBV reactivation. Many 
HBV-infected patients are unconscious of their disease 
or risk factors. An appeal from scientific societies for 
physicians to spend enough time to assess patients for 
HBV risk factors prior to begin immunosuppression 
therapy is mandatory.
Most management guidelines recommend to 
check hepatitis B virus markers, such as HBsAg and 
anti-HBc in those who are to undergo chemotherapy. 
Prophylactic therapy is recommended before the 
start of chemotherapy until at least 6 or 12 months 
after completing chemotherapy or when treatment 
end points are reached. There is no consensus on the 
length of prophylactic treatment before the patients are 
treated with immunosuppressive therapy, and for how 
long this therapy should be extended once treatment is 
completed. Choice of antiviral drugs for prophylaxis 
such as lamivudine, telbivudin, entecavir or tenofovir, 
depends on viral load and duration or therapy. 
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Table 5 : Recommendations for treatment and follow-up in different clinical scenarios, according to APASL, AASLD and EASL guidelines : [2]
recommendation in different clinical scenarios
HBsAg (+), HBV DNA 
> 2000 U/mL
HBsAg (+), HBV DNA < 
2000 U/mL
HBsAg(-),
 antiHBc (+)
HBsAg (-), 
antiHBc (-), 
antiHBs (-)
HBV-HCC TACE
Action Treat Treat Closed monitor
Treat if HBV DNA (+) or Rituximab/ 
stem cell transplant
vaccination Treat
Onset Before IS Before IS Before IS - Before IS
Duration 6-12 mo (except CI) 6-12 mo (except CI) 6-12 mo - -
Drugs Short IS : LAM (Ldt)
Preferred ETV/TDF
Short IS: LAM (Ldt)
(ETV/TDF)
Short IS: LAM (Ldt)
(ETV/TDF)
- LAM (ETV/TDF)
Follow up Every 1-3mo / treat if HBV (+) - -
CI : clinical indication; IS : immunosuppressant, HBsAg : Hepatitis B surface antigen; antiHBc : Hepatitis B core antibody; antiHBs : Hepatitis B surface antibody; 
HBV : Hepatitis B virus, HCC : Hepatocellular carcinoma,  TACE : Transarterial chemoembolization, LAM : Lamivudine, ETV : Entecavir, TDF : Tenofovir, LdT 
: Telbivudine (only listed as an option in AASLD guideline)
